RXRα Agonist

HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity.

AGN-191659 is an orally active RAR/RXR agonist with EC₅₀ values of 11 nM, 23 nM, and 37 nM for RXRα, RARβ, and RARγ, respectively. AGN-191659 activates RXRα, RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia.

GW0791 (Compound 3) is an RXRα agonist with an EC₅₀ of 5 nM. GW0791 can be used for cancer research.

RXR agonist 3 (Compound 35) is a potent, partial RXR agonist (EC₅₀s: 3, 3, 8 nM for RXRα, RXRβ, RXRγ, respectively). RXR agonist 3 can be used in the research of Alzheimer's disease, multiple sclerosis, and lymphoma.